---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000024"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:44:54.494887+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement

## Summary
- Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.
- Pro forma cash ~$825M after $450M private placement closed Jan 15, 2025.
- Batoclimab MG pivotal and CIDP period 1 results expected by March 31, 2025.
- IMVT-1402: 6 INDs cleared; pivotal GD and D2T RA studies enrolling with autoinjector.
- Batoclimab GD additional data (6-month remission) summer 2025; TED top-line H2 2025.

## SEC filing metadata
- accession: 0001764013-25-000024
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/0001764013-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/imvt-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000024
- JSON: https://secwatch.observer/filing/0001764013-25-000024.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.